Le Lézard4d
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program ... Annual Report on Form 10-K, which has been ...
pharmaphorum1d
How tech-driven hubs in specialty pharmacy can improve the patient experience
specialty pharmacies are responsible for distributing therapies to the patient on behalf of the manufacturer, so they need a centralised application to support the entire process of patient intake ...
pharmaphorum3d
A history of Novartis
In 1970, Ciba and Geigy merged to form Ciba-Geigy Ltd. Ten years ... According to Novartis, the Glivec International Patient Assistance Program has provided free treatment to nearly 27,000 ...
AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
Yahoo Finance4d
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age ...
AbbVie, Regenxbio provide updates on ABBV-RGX-314 clinical program
AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular ...
Yahoo Finance4d
AbbVie (NYSE:ABBV) Is Paying Out A Larger Dividend Than Last Year
It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...
Stockhouse4d
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in ... "Risk Factors," of AbbVie's 2023 ...
Seeking Alpha3d
AbbVie Has Immense Cash Flow Potential
AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...
FierceBiotech10d
AbbVie exercises first $40M option to advance Capsida-partnered CNS gene therapy
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.
Mena FN10d
Capsida Announces Abbvie Opt-In For First Genetic Medicine Program From Neurodegenerative Disease Collaboration
Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $ ...